EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

Pharmacokinetics, Safety, and Tolerability of Cedirogant in Healthy Japanese and Chinese Adults

Mohamed-Eslam F Mohamed, Yuli Qian, Ronilda D'Cunha, Shuai Hao, Roberto Carcereri De Prati, Gweneth F Levy, Kinjal Hew, Wei Liu

Clinical Pharmacology in Drug Development · 2024

DOI: 10.1002/cpdd.1386 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2024. Verfasst von Mohamed-Eslam F Mohamed und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, AbbVie, North Chicago, IL, USA. Hauptthemen laut MEDLINE: Dose-Response Relationship, Drug, Retinoic Acid Receptor gamma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cedirogant is an inverse agonist of retinoic acid‐related orphan receptor gamma, thymus (RORγt) developed for treatment of psoriasis. This study aimed to characterize pharmacokinetics, pharmacodynamics, safety, and tolerability of cedirogant following a single oral dose in Japanese participants and multiple oral doses in Japanese and Chinese participants. The single doses evaluated in healthy Japanese participants were 75, 225, and 395 mg. The multiple doses evaluated in both healthy Japanese and Chinese participants was 375 mg once daily for 14 days. Cedirogant plasma exposure increased dose proportionally with administration of single doses. Maximum cedirogant plasma concentration was reached within a median time of 4‐5 hours after dosing. The harmonic mean elimination half‐life ranged from 19 to 25 hours. Cedirogant pharmacokinetics were similar between Japanese and Chinese participants. Compared with healthy Western participants in a cross‐study analysis, steady‐state cedirogant plasma exposure was 38%‐73% higher in Japanese or Chinese participants. Ex vivo interleukin‐17 inhibition increased in a dose‐dependent manner and was maximized by 375 mg once‐daily doses. The cedirogant regimens tested were generally well tolerated, and no new safety issues were identified. The results supported enrollment of Japanese and Chinese subjects in subsequent clinical trials for cedirogant.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dose-Response Relationship, DrugRetinoic Acid Receptor gammaAdultFemaleHumansMaleMiddle AgedYoung AdultAdministration, OralChinaCross-Over StudiesEast Asian PeopleHalf-LifeHealthy VolunteersInterleukin-17Japan

Stichwörter der Autor:innen

RORγtcedirogantpharmacokineticspsoriasis

Substanzen

Interleukin-17Retinoic Acid Receptor gamma

Autor:innen und Institutionen

  • Clinical Pharmacology, AbbVie, North Chicago, IL, USA.
  • Discovery and Exploratory Statistics, AbbVie, North Chicago, IL, USA.
  • Immunology Development, AbbVie, Ludwigshafen, Germany.
  • Pharmacovigilance and Patient Safety, AbbVie, North Chicago, IL, USA.
  • Precision Medicine Immunology, AbbVie, North Chicago, IL, USA.

Förderung

  • AbbVie

Zitieren

APA

Mohamed, M. F., Qian, Y., D'Cunha, R., Hao, S., Carcereri De Prati, R., Levy, G. F., Hew, K., & Liu, W. (2024). Pharmacokinetics, Safety, and Tolerability of Cedirogant in Healthy Japanese and Chinese Adults. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1386

Vancouver

Mohamed MF, Qian Y, D'Cunha R, Hao S, Carcereri De Prati R, Levy GF, et al. Pharmacokinetics, Safety, and Tolerability of Cedirogant in Healthy Japanese and Chinese Adults. Clinical Pharmacology in Drug Development. 2024. doi:10.1002/cpdd.1386

BibTeX
@article{Mohamed2024,
  author = {Mohamed, Mohamed-Eslam F and Qian, Yuli and D'Cunha, Ronilda and Hao, Shuai and Carcereri De Prati, Roberto and Levy, Gweneth F and Hew, Kinjal and Liu, Wei},
  title = {Pharmacokinetics, Safety, and Tolerability of Cedirogant in Healthy Japanese and Chinese Adults},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2024},
  doi = {10.1002/cpdd.1386}
}
Kostenlos starten →